All In Biotech

Drug Trial Radar · NCT07587242

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

May 2029

Study completion Jul 2030

Sponsor

Lead sponsor
Avidity Biosciences, Inc.Industry
Sponsor type
Industry
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Conditions

  • Muscular Dystrophies
  • Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
  • Muscular Disorders, Atrophic
  • Muscular Disease
  • Musculoskeletal Diseases
  • Neuromuscular Diseases (NMD)
  • Nervous System Diseases
  • Genetic Diseases
  • X-Linked
  • Hereditary
  • Neonatal Disease
  • Duchene Muscular Dystrophy
  • Congenital
  • DMD

Interventions

  • AOC 1044Drug

    AOC 1044 will be administered by intravenous (IV) infusion

  • PlaceboDrug

    Placebo will be administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Time to Rise (TTR) Velocity at Week 54Time frame: Baseline, Week 54

Locations

20 sites in 10 countries. Site status is shown where the registry gives one.

  • The Children's Hospital at Westmead

    Westmead, New South Wales, Australia · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Centre Hospitalier Régional de la Citadelle

    Liège, Belgium · Recruiting

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada · Recruiting

  • CHU de Nantes - Hotel-Dieu

    Nantes, France · Recruiting

  • AP-HP Hospital Armand-Trousseau

    Paris, France · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    München, Germany · Recruiting

  • Istituto Giannina Gaslini

    Genova, Italy · Recruiting

  • Fondazione Serena ETS - Centro Clinico NeMO Milano

    Milan, Italy · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universitario Cattolica del Sacro Cuore

    Roma, Italy · Recruiting

  • Academisch Ziekenhuis Leiden

    Leiden, Netherlands · Recruiting

  • Uniwersyteckie Centrum Kliniczne, Gdańsk

    Gdansk, Poland · Recruiting

  • Hospital Sant Joan de Deu

    Barcelona, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Viamed Santa Angela De la Cruz - FutureMeds Spain

    Seville, Spain · Recruiting

  • Royal Victoria Infirmary

    Newcastle, United Kingdom · Recruiting

  • University of Oxford and Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.